> top > docs > PubMed:33041111 > annotations

PubMed:33041111 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 924-930 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T2 1060-1063 Body_part denotes V-2 http://purl.org/sig/ont/fma/fma13443|http://purl.org/sig/ont/fma/fma68615

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 0-8 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T2 141-149 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 248-256 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T4 465-473 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 479-487 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T6 1052-1056 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 121-122 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T2 200-203 http://purl.obolibrary.org/obo/PR_000001343 denotes aim
T3 621-625 http://purl.obolibrary.org/obo/CLO_0008416 denotes peer
T4 621-625 http://purl.obolibrary.org/obo/CLO_0050081 denotes peer
T5 677-681 http://purl.obolibrary.org/obo/CLO_0008416 denotes peer
T6 677-681 http://purl.obolibrary.org/obo/CLO_0050081 denotes peer
T7 764-765 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T8 924-930 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T9 965-966 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T10 1140-1141 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T11 1379-1380 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 550-568 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T2 575-584 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T3 858-869 Chemical denotes chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T4 871-873 Chemical denotes CQ http://purl.obolibrary.org/obo/CHEBI_3638
T5 876-894 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T6 902-912 Chemical denotes antivirals http://purl.obolibrary.org/obo/CHEBI_22587
T7 1057-1059 Chemical denotes Co http://purl.obolibrary.org/obo/CHEBI_27638
T8 1097-1107 Chemical denotes remdesivir http://purl.obolibrary.org/obo/CHEBI_145994
T9 1179-1198 Chemical denotes lopinavir-ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T10 1179-1188 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T11 1189-1198 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T12 1200-1209 Chemical denotes ribavirin http://purl.obolibrary.org/obo/CHEBI_63580
T13 1214-1224 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T14 1225-1229 Chemical denotes beta http://purl.obolibrary.org/obo/CHEBI_10545
T15 1269-1282 Chemical denotes dexamethasone http://purl.obolibrary.org/obo/CHEBI_41879

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1 0-10 Species denotes SARS-CoV-2 Tax:2697049
18 141-149 Disease denotes COVID-19 MESH:C000657245
19 248-258 Species denotes SARS-CoV-2 Tax:2697049
20 392-396 Gene denotes JAMA Gene:50848
21 465-473 Disease denotes COVID-19 MESH:C000657245
22 479-489 Species denotes SARS-CoV-2 Tax:2697049
23 516-589 Gene denotes OR (treatment)) OR (vaccine)) OR (hydroxychloroquine)) OR (antiviral)) OR
24 858-869 Chemical denotes chloroquine MESH:D002738
25 871-873 Chemical denotes CQ MESH:D002738
26 876-894 Chemical denotes hydroxychloroquine MESH:D006886
27 896-899 Chemical denotes HCQ MESH:D006886
28 1052-1063 Species denotes SARS-Co-V-2 Tax:2697049
29 1097-1107 Chemical denotes remdesivir MESH:C000606551
30 1179-1198 Chemical denotes lopinavir-ritonavir MESH:C558899
31 1200-1209 Chemical denotes ribavirin MESH:D012254
32 1269-1282 Chemical denotes dexamethasone MESH:D003907
33 1305-1314 Disease denotes mortality MESH:D003643

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-97 Sentence denotes SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.
T2 98-111 Sentence denotes INTRODUCTION:
T3 112-196 Sentence denotes There is a pressing need for COVID-19 transmission control and effective treatments.
T4 197-341 Sentence denotes We aim to evaluate the safety and effectiveness of SARS-CoV-2 pharmacologic therapies as of August 2, 2020 according to study level of evidence.
T5 342-350 Sentence denotes METHODS:
T6 351-428 Sentence denotes PubMed, ScienceDirect, Cochrane Library, JAMA Network and PNAS were searched.
T7 429-603 Sentence denotes The following keywords were used: ((COVID-19) OR (SARS-CoV-2)) AND ((((((therapeutics) OR (treatment)) OR (vaccine)) OR (hydroxychloroquine)) OR (antiviral)) OR (prognosis)).
T8 604-664 Sentence denotes Results included peer-reviewed studies published in English.
T9 665-673 Sentence denotes RESULTS:
T10 674-803 Sentence denotes 15 peer-reviewed articles met study inclusion criteria, of which 14 were RCTs and one was a systematic review with meta-analysis.
T11 804-975 Sentence denotes The following pharmacologic therapies were evaluated: chloroquine (CQ), hydroxychloroquine (HCQ), antivirals therapies, plasma therapy, anti-inflammatories, and a vaccine.
T12 976-987 Sentence denotes CONCLUSION:
T13 988-1262 Sentence denotes According to level 1 evidence reviewed here, the most effective SARS-Co-V-2 pharmacologic treatments include remdesivir for mild to severe disease, and a triple regimen therapy consisting of lopinavir-ritonavir, ribavirin and interferon beta-1b for mild to moderate disease.
T14 1263-1354 Sentence denotes Also, dexamethasone significantly reduced mortality in those requiring respiratory support.
T15 1355-1449 Sentence denotes However, there is still a great need for detailed level 1 evidence on pharmacologic therapies.